|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||18.10 - 18.69|
|52 Week Range||18.10 - 26.50|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||N/A|
|Expense Ratio (net)||0.74%|
A new study deciphers for the first time the cannabis plant's biological blueprint for producing two molecules thought to have anti-inflammatory properties, a discovery that could pave the way for expanded use of cannabis as medicine.
With more than 600 million inhabitants, the region's legal cannabis market is expected to reach $13 billion by 2028. Benzinga spoke with Carol Ortega, the managing director and founder of Muisca Capital Group, a Latin America-focused venture capital firm serving the legal cannabis industry in the U.S. and Colombia. Muisca Capital Group is the first Latino-focused venture capital firm providing professional services to the legal cannabis industry in the U.S. and Colombia, Ortega said.
“GEN!US is curated intentionally to aid the thinking process, open neural pathways and break down mental barriers for today’s modern cannabis connoisseur,” according to a press release. A GEN!US spokesperson says the brand was created for creative people, crafted by a group of microbiologists, chemists, engineers and cannabis veterans who partnered up with their favorite cannabis growers. “GEN!US is not a title, but an untapped destination within us that is waiting to be unleashed,” 25-year-old CEO Chris Clifford said.
Ever since it reported quarterly results on June 13, HEXO (NYSE:HEXO) stock continued its downtrend. At a recent price of $4.23, the stock is getting close to falling below the symbolic $1 billion CAD ($750 million) market capitalization. Growing bearishness around cannabis stocks and the uncertainties around the company's growth prospects are hurting HEXO stock. Then, last month, its key brand executive stepped down from the position. What will it take to get investors interested in the company again?Source: Shutterstock On July 18, Hexo's co-founder and chief brand officer, Adam Miron, stepped down from his position. He will retain his seat on the Hexo Board of directors. Miron may have decided to leave the company because of regulator Health Canada slowing the pace of growth in the industry. Excessive regulations and slow decision-making took away the growth momentum for Hexo and the cannabis market in the last year. Sebastien St-Louis, Hexo's co-founder, said just about what you'd expect: "I respect his decision to take on new challenges and focus on his true passion: building."The Hexo stock price is down more than 40% in the past three months, versus the near-25% decline in the cash-heavy exchange-traded fund AdvisorShares Pure Cannabis ETF (NYSEArca:YOLO). Hexo is the fifth-largest equities holding in the marijuana fund's 28 constituents, at 4.72% of the portfolio. YOLO has a ~17% cash position.InvestorPlace - Stock Market News, Stock Advice & Trading Tips New C's in the C-suiteIn its Q3 2019, Hexo added a new COO, Donald Courtney, who has notable experience at Pepsi Bottling Group, Mars, and as head of MedReleaf. Michael Monahan joined the company as its new CFO. His chief responsibility is driving Hexo's global strategy. By expanding outside of the U.S., the company will have less geographic risks and a bigger addressable market. As more countries legalize cannabis, Hexo's addressable market will expand. These additional executive members will lead the 25 PhDs that the company has on staff. * 10 Stocks Under $5 to Buy for Fall Last quarter, Hexo secured around 200,000 kilograms of hemp supply for CBD and non-THC cannabinoid extraction for fiscal 2020. It has a secondary supply agreement of around 60,000 kilograms of hemp that will be supplied in the next two quarters. Hexo is gearing up for upcoming demand in edibles and concentrates, pending legalization in October in Canada. It signed a multi-year extraction agreement with Valens. This will add 30,000 kilograms of output in the first year and 50,000 kilograms of cannabis and hemp biomass in the second year. Collectively, Hexo has a near-term target of having 150,000 kilograms of supply. Greenhouse Helps Double OutputTo date, Hexo sold over 7.5 million grams of adult-use medical cannabis to Canadians. In the last quarter, sales increased 9% to 2,700 adult-use grams and grams equivalent. As its distribution across the Great White North expands, expect sales from this segment growing.Hexo produced ~9.8 tons of dried gram equivalent (9,800 kilograms). Output increased 98% sequentially after yields increased from its 250,000-square-foot B6 greenhouse. It also benefited from the first harvest at its 1-million-square-foot B9 greenhouse.Looking ahead, the company is prepared for the legalization of edibles and concentrates in October 2019. But the big risk here is any Canadian regulatory delays. This would push Hexo's phase two adult-use output into December. To mitigate these risks, the company is developing CBD gummies, a premium vape line, and cannabis-infused beverages in partnership with Truss, its joint venture with Molson Coors Canada that was announced in October 2018. Pricing HeadwindA drop in gross margins is a major risk for Hexo shareholders. Though the company reported a gross margin of 49% on net revenue, it expects price pressures ahead, as CEO St. Louis said on the recent conference call. "We do expect over the next 24 months as there is significant pricing compression that the flower might gradually gross margins towards the 40% level," he told participants. * 10 Undervalued Stocks With Breakout Potential Despite the pricing compression, Hexo expects its introduction of more advanced products will push the gross margin back toward 50%. Hexo Stock Valuation and Your TakeawayHexo will report quarterly results on Sept. 12 after the market closes. Two analysts who cover Hexo stock have a 125% upside target price (per TipRanks). Realistically, number-crunching a fair value on Hexo at this time is difficult (per finbox.io).Forecasting its revenue is difficult without knowing when the Canadian government will finalize the regulations. Hexo forecast FY2020 revenue of over $400 million CAD, which is multiples bigger than its $15.9 million CAD ($63.9 million CAD annualized) reported in the third quarter.Investors are taking a wait and see approach. As stocks like Tilray (NASDAQ:TLRY) or CannTrust (NASDAQ:CTST) fall, investors want more proof that revenue growth is sustainable and profits are achievable. HEXO stock investors need the market warming up to cannabis stocks again. It must also meet its revenue projections to win back investors.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post Why Investors Should Trade Cautiously With Hexo Stock appeared first on InvestorPlace.
Headset has released a new industry report with insights about cannabis-infused beverages. The firm took a deep dive into the stats of the beverage market including data from Colorado, Washington and Nevada, hitting points about infused beverages, a breakdown of what is selling by state, data on who is drinking what and more. Headset concluded the cannabis-infused beverage category meets a need that people didn’t even know they had.
After three new marijuana exchange traded funds launched in July, bringing the total of cannabis ETFs listed in New York to five, another competitor could be coming to market. What Happened AdvisorShares, ...
Ortiz had three consecutive wins before the fight, with one being a 0:16 submission against Jeremy Screeton. He was also noticeably bigger than Shamrock, and had more fights under his belt. Despite landing some pretty heavy blows in the first three rounds, Ortiz did begin to tire by the fourth round, and that’s when Shamrock dropped a calamitous elbow that landed with what I can only imagine being similar to the force of a Nimitz class aircraft carrier. You see, these guys aren’t street thugs. They’re not hot-headed bar fighters looking to blow off some steam. These guys are some of the most gifted and well-disciplined athletes on the planet. The sacrifice and dedication it takes to get to this level is almost inhuman. But it’s also the kind of sacrifice and dedication that can make these guys successful in anything they choose to do. And there is no better example of this than Frank Shamrock.
A recent user survey conducted by Investing.com revealed that state legislation regarding marijuana legalization is driving investor interest in pot stocks. Looking into 8 million users across the U.S., they found that investors in states that had legalized marijuana showed the a much greater interest in investing in the substance, with Maine, Massachusetts, Michigan, Alaska and California ranking as the top five states for investor interest. Investing.com's partner on the survey, SEMrush also found a drastic increase in Google searches for pot socks in each of the aforementioned states following legalization, in excess of 100% in most cases.
Article originally posted on LA Weekly, provided to Benzinga Cannabis by the author. A new national advocacy organization has launched in Los Angeles to advocate and educate lawmakers on the path towards federal cannabis legalization. Mr. Jason Beck, a longtime Angeleno who was born with cerebral palsy and an early medical cannabis patient, spearheaded the creation of the new organization. The Global Alliance for Cannabis Commerce (GACC) will focus on legislation including, cultivation, manufacture, distribution, public safety, and taxation of medical and adult-use cannabis.
Since Michigan voters approved and created the Michigan Regulation and Taxation of Marijuana Act (MRTMA) in late 2018, which legalized recreational usage of marijuana within certain parameters, the state has become a hub of cannabis startups and investors. Both agree Michigan represents an enormous opportunity for companies and investors.
The speculative nature of the cannabis industry has led to some wild swings in pot stocks, but an ETF's big trades are also adding to the volatility.
Oregon is one step closer to voting in November 2020 to legalize medicinal psilocybin mushrooms for adults in the state. While current laws prohibit the use and possession of psilocybin, a hallucinogenic compound from "magic mushrooms," activists in the state are championing the Oregon Psilocybin Services Act. Under the proposed measure, the Oregon Health Authority (OHA) would establish a regulatory program allowing for the production, processing, delivery, possession and administration of psilocybin.
By the end of 2019, retail sales are expected to top $12 billion - an increase of 35%, according to Marijuana Business. It’s one thing to offer the best bud, but in today’s retail landscape where new brands and product categories are emerging, it’s important to stay current with shifting trends and tastes of consumers. As the cannabis industry’s wholesale marketplace, LeafLink works with thousands of retailers to simplify their purchasing processes.
By Aaron Silverman, President of MediaJel . New companies tend to cultivate similarly. Build a winning team and culture. Plan and establish your vision of success – but maintain flexibility. Structure ...
While cannabis remains illegal under federal law, state-approved medical marijuana programs continue to sprout like weeds across the United States – and in other parts of the world, too. The key that allows you to reap the benefits of the cannabis plant is a state-specific identification card called the medical marijuana card (also known as a cannabis card or weed card). As of July 2019, the use of cannabis for medicinal purposes has been legalized in 33 states, along with Washington, D.C. As the first state to legalize medical marijuana, California drew the initial blueprint with the 1996 passage of the Medical Use of Marijuana Initiative.
The multi-billion-dollar cannabis industry in the U.S. is largely restricted to cash-only transactions. Will Congress or technology companies be the first to provide a solution for this growing industry?
After three incredibly successful versions of the Cannabis Capital Conference, the Benzinga events team is bringing the next iteration to our hometown of Detroit. The Cannabis Capital Conference takes place Aug. 15 at the Westin Book Cadillac in downtown Detroit. Who Comes To The Conference? The most important part of Benzinga events remains the strong focus on connecting well-vetted companies with a high tier of institutional and accredited investors.
Human Immunodeficiency Virus (HIV) may no longer be a death sentence, but it is a life sentence for those who are coping with the chronic symptoms of the virus. There are dozens of HIV/AIDS drugs on the market which reduce viral loads in the body and ease certain symptoms, but also cause unpleasant side effects such as headache and nausea. Well-known as an appetite stimulant, cannabis has been used to manage the anorexia and wasting disease symptoms of HIV/AIDS, but the plant might be able to go even further beyond this basic treatment.
CannabisMD recently compared relative search volumes for CBD and Beyonce, Kim Kardashian, kale and veganism. The findings were a bit surprising. “Looking at 2018 trends, CBD grew by over 260 percent in ...
Argentina will hold its first big cannabis conference, Expo Cannabis, Oct. 4 -6 at the La Rural event hall in Buenos Aires. The South American country is far behind its tiny neighbour Uruguay in terms of cannabis legalization, but things could soon change. Argentina’s cannabis industry is literally seeing its first sprouts.
Why is the hemp plant so good for us? Thankfully, doctors can run tests for these deficiencies and work to find hormone replacement therapy or medicine and therapy that can help with the myriad issues caused by an upset to the balance our bodies want and need.
It’s not even 2020, but the 2020 Election is already turning personal and combative between presidential candidates for the Democratic nomination. This week saw Sen. Cory Booker aim directly at former Vice President Joe Biden, who released his extensive plan for criminal justice reform, which included Biden’s proposal to reclassify marijuana as a Schedule II drug. Among Democrat presidential candidates, Biden is the least progressive on marijuana reform with his views barely evolving since 1989.
Jackson Tilley’s "Billion Dollar Dimebag," which hits bookshelves Sept. 17, is an exploration of the intersection of business, diversity and THC. Before "Billion Dollar Dimebag," Tilley's experiences in the cannabis sphere were almost mundane. After college, he began working at Organa Brands and later at SLANG Worldwide.